Potential Novel Target Discovery
VANCOUVER, BC – (December 3, 2018) – Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company” or “Nash Pharma”) is pleased to announce that in a recent in vivo animal study for Crohn’s disease (CD), NP-178, its lead compound for the treatment of ulcerative colitis (UC), performed equivalent to and in some measurements, better than 5-ASA, a current global standard of care treatment for inflammatory bowel disease (IBD). A new potential treatment for CD could lead to an orphan drug designation, which could help expedite its availability to patients.There are a number of countries globally, that have an orphan drug program in place whereby companies that develop drugs for certain rare diseases enjoy enhanced collaboration with the regulatory authority, incentives, marketing exclusivity, and improved pricing and reimbursement.
In addition, the Company announces the discovery of a second compound, NP-120 that was also active in both of the Company’s UC and CD in vivo studies. Both NP-178 and NP-120 are currently used clinically for the treatment of neurological diseases. The Company believes that NP-178 & NP-120 may modulate novel targets for IBD and is consistent with the concept that there may be a connection or pathway between the brain and the gastro intestinal system that could be modulated for therapeutic treatment opportunities.
Data from this study demonstrated statistically significant improvements in multiple measurements over multiple time points relevant to CD including:
- Body weight (p<0.001), occult positivity (p<0.05), colon weight (p<0.05), colon length (p<0.001) and the colon weight/length ratio (p<0.001)
- The drug compared very favourably to the control, 5-ASA, the current standard of care for IBD.
- No negative side effects were observed.
- NP-178 is a repurposed, orally delivered neurological drug.
- Body weight (p<0.01), colon length (p<0.001) and colon weight/length ratios (p<0.01)
- The drug compared very favourably to the control, 5-ASA, the current standard of care for IBD in both the CD and an earlier UC study
- No negative side effects were observed.
- NP-120 is a repurposed, orally delivered neurological drug.
“This additional study not only validated our original discovery of both NP-178 and NP-120 in an independent in vivo study for CD, but has also opened up an exciting new opportunity because CD is an orphan disease”, said Christopher J. Moreau CEO of Nash Pharma. “We look forward to updating the market with additional information on these compounds shortly”
The Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 Report shows that the global inflammatory bowel diseases (IBD) drug market is estimated at $6.7B in 2017 and $7.6B in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.
About Nash Pharmaceuticals Inc.
Nash Pharma is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.
For more information, visit https://nashpharmaceuticals.com/.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.